Bioactive compounds of Plukenetia volubilis L. as c-Met tyrosine kinase ınhibitors for gastric anticancer: in silico study
Gastric cancer remains one of the most aggressive malignancies worldwide due to its high incidence and mortality rates. Although tyrosine kinase inhibitors have demonstrated therapeutic efficacy, their use is often associated with adverse effects, highlighting the need for safer anticancer agents. Plukenetia volubilis...